Medication Adherence App for Bone Marrow Transplant Care
(Bmt4me 2 Trial)
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify whether participants must stop taking their current medications. It focuses on using an app to help with medication adherence for children post-transplant.
What data supports the effectiveness of the BMT4me 2.0 app treatment for improving medication adherence in bone marrow transplant care?
Research shows that digital health tools like the BMT4me app can help improve medication adherence by sending reminders and tracking medication use, which is crucial for children undergoing bone marrow transplants. Similar apps have shown promise in enhancing symptom monitoring and improving outcomes in patients with complex conditions.12345
Is the BMT4me app safe for use in humans?
The BMT4me app has been used in studies to help monitor medication adherence in children undergoing bone marrow transplants, and no safety issues have been reported. It acts as a virtual assistant to remind caregivers about medication schedules and track symptoms, aiming to improve health outcomes.13467
How is the BMT4me 2.0 app treatment different from other treatments for bone marrow transplant care?
The BMT4me 2.0 app is unique because it acts as a 'virtual assistant' to help caregivers manage medication schedules for children who have undergone bone marrow transplants, providing real-time tracking and reminders, which is not typically offered by standard care or other digital health interventions.12345
What is the purpose of this trial?
This is a mixed methods, prospective longitudinal pilot RCT to evaluate the 1) acceptability of a newly developed mHealth app (BMT4me), 2) the feasibility of enrolling and retaining caregivers of children in the acute phase post-HSCT, and 3) the potential efficacy of an mHealth app on adherence to immunosuppressants in post-HSCT children discharged during the acute phase.
Eligibility Criteria
This trial is for primary caregivers who speak English and have an iOS or Android device. Their children must be aged 2-12, receiving immunosuppression post-allogeneic bone marrow transplant, and discharged before Day 100 of immunosuppression tapering. Adults unable to consent and pregnant women cannot participate.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Acute Phase Post-HSCT
Participants are monitored for medication adherence and receive the BMT4me 2.0 app or usual care at discharge
Follow-up
Participants are monitored for safety and effectiveness after the acute phase
Treatment Details
Interventions
- BMT4me 2.0 app
Find a Clinic Near You
Who Is Running the Clinical Trial?
Micah Skeens
Lead Sponsor
National Institute of Nursing Research (NINR)
Collaborator